The Duke Reading Center, which specializes in the analysis of retinal images, collaborated with Sina Farsiu, professor in the departments of ophthalmology and biomedical engineering, to play a pivotal ...
The Ohio State University Department of Art Faculty Exhibition is currently on view at the Urban Arts Space. The works run ...
A West Coast biotech entrepreneur says he’s secured $30 million to form a public-benefit company to study how to safely create genetically edited babies, marking the largest known investment into the ...
In a world first, a bespoke gene-editing therapy benefitted one child. Now reseachers plan to launch a clinical trial of the ...
The U.S. government is divesting from mRNA vaccines, but will other uses of the technology be spared? In a time of ...
A top US regulator plans to unveil a faster approach to approving custom gene-editing treatments, a move designed to unleash a wave of industry investment that will yield cures for patients with rare ...
The Boston biotech founded by Harvard professor David Sinclair is testing whether cellular reprogramming can turn back the ...
The neurologic disease called chronic traumatic encephalopathy or CTE has most often been found in people who experienced repeated blows to the head while playing contact sports and there’s now ...
Seven years after the first gene-edited babies were revealed, biotech startup Manhattan Genomics is reviving the idea of ...
The Company treated the first patient in the pivotal Phase 3 OVATION 3 Study in July 2025 and is working with trial investigators to expand clinical sites and accelerate enrollment. Four sites have ...
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of one abstract for late-breaking oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback